Indication

Bullous pemphigoid

Bullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age. Read more about Bullous pemphigoid

3 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Bullous pemphigoid therapies.

Showing 1–3 of 3 drugs

DUPIXENT (dupilumab)

ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.

DUPIXENT PEN (dupilumab)

ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.
Filter & compare in the drug finder →Opens the drug finder with Bullous pemphigoid preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Bullous pemphigoid.

Bullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age.

It is primarily mediated by circulating IgG autoantibodies directed against hemidesmosomal structural antigens—specifically BP180 and BP230—at the dermoepidermal junction, which triggers complement activation, inflammatory cell recruitment, and tissue separation.

Clinically, the condition manifests with severe pruritus alongside tense, fluid-filled bullae and erosions arising on normal-appearing, urticarial, or erythematous skin, most commonly involving the flexural extremities and lower abdomen.

Mucosal membrane involvement can occur, though it is usually mild and less prominent than cutaneous disease.

Personalize your experience

Follow Bullous pemphigoid and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it